89Zr-durvalumab

N/A

Report date: 2025/09/12 15:57:57

Base Information

Drug Name89Zr-durvalumab

Drug Alias NameN/A

ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6]

Mechanisms of ActionProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesRadboud University Nijmegen

China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Medical Center

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A